AUSTIN, Texas, Aug. 2, 2016 /PRNewswire/ -- ASPiRA LABS, a Vermillion company (NASDAQ: VRML), today announced an agreement has been reached with Sacramento-based Sutter Valley Medical Foundation (d/b/a Gould Medical Foundation) for coverage of OVA1, Vermillion's ovarian cancer risk assessment test commercialized by ASPiRA LABS.
"We are pleased to announce OVA1 coverage expansion with Gould Medical Foundation, a California network provider," said Valerie Palmieri, President and CEO of Vermillion, Inc. "Reaching more women with our technology is our mission. Providing testing that can improve outcomes in ovarian cancer, where the mortality rate has not changed in 40 years, is our passion. OVA1, compared to modified ACOG criteria, aids in the detection of all ovarian cancer stages, including stage 1 and 2 which may help identify the most suitable provider for optimal patient care. Expanding access to OVA1 is our goal, so that we can serve women at an elevated risk for ovarian cancer. These agreements with Gould Medical Foundation are part of our campaign to pursue managed care coverage agreements throughout 2016. Our focus is to continue to expand OVA1 test adoption, to build our data repository further and to expand our clinical studies in order to demonstrate the 'total cost of care' benefit of OVA1 to healthcare systems."